Blueprint Medicines Corp: Ind for Wild-Type Kit Inhibitor Blu-808 on Track for Filing in Q2
Blueprint Medicines Corp:野生型试剂盒抑制剂Blu-808的申请有望在第二季度申报
Blueprint Medicines Corp: Ind for Wild-Type Kit Inhibitor Blu-808 on Track for Filing in Q2
Blueprint Medicines Corp:野生型试剂盒抑制剂Blu-808的申请有望在第二季度申报
使用浏览器的分享功能,分享给你的好友吧